Skip to content

Price / book at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
25.2×+15.2×
ALN
Alnylam PharmaceuticalsALNY
40.8×-41.2×
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
22.1×+11.8×
Royalty Pharma logo
Royalty PharmaRPRX
2.1×+0.7×
AbbVie logo
AbbVieABBV
261×+221×
Revvity logo
RevvityRVTY
1.4×-0.3×

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Calculated from Arrowhead Research’s reported figures.

Based on the most recent quarter.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's price / book?
Arrowhead Research (ARWR) reported price / book of 14.3× in Q1 2026.
How has Arrowhead Research's price / book changed year-over-year?
Arrowhead Research's price / book increased by 458.6% year-over-year, from 2.6× to 14.3×.
What is the long-term trend for Arrowhead Research's price / book?
Over 5 years (2020 to 2025), Arrowhead Research's price / book has grown at a 1.0% compound annual growth rate (CAGR), from 9.7× to 10.2×.
What does price / book mean?
How the market price compares to the company's accounting net worth.
How do you interpret price / book?
Below 1.0 can flag a market discount to book value (common for distressed or asset-heavy firms); high values reflect intangible value the balance sheet doesn't capture. Most informative for financials and asset-heavy businesses.
How does price / book compare across companies?
A core valuation gauge for banks and insurers; weak for asset-light firms where book value understates economic value.